Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
294.01B
Market cap294.01B
Price-Earnings ratio
33.51
Price-Earnings ratio33.51
Dividend yield
2.79%
Dividend yield2.79%
Average volume
11.42M
Average volume11.42M
High today
$121.90
High today$121.90
Low today
$118.84
Low today$118.84
Open price
$121.50
Open price$121.50
Volume
10.93M
Volume10.93M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$76.66
52 Week low$76.66

Stock Snapshot

With a market cap of 294.01B, Merck(MRK) trades at $119.25. The stock has a price-to-earnings ratio of 33.51 and currently yields dividends of 2.8%.

As of 2026-06-14, Merck(MRK) stock has fluctuated between $118.84 and $121.90. The current price stands at $119.25, placing the stock +0.3% above today's low and -2.2% off the high.

The Merck(MRK)'s current trading volume is 10.93M, compared to an average daily volume of 11.42M.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $76.66.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $76.66.

MRK News

Simply Wall St 1d
The Bull Case For Merck Could Change Following First PD-1 Plus HIF-2α Adjuvant Approval

Earlier this week, Merck reported that the FDA approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, as adjuvant therapy for adults with clear...

The Bull Case For Merck Could Change Following First PD-1 Plus HIF-2α Adjuvant Approval
MarketWatch 2d
Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch

...

Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch
TipRanks 2d
FDA approves Keytruda-Welireg combination for adjuvant treatment of ccRCC

Merck (MRK) announced the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, Merck’s anti-PD-1 therapies, each in combination with WELIREG,...

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More MRK News

Seeking Alpha 2d
Merck wins FDA label expansion for Welireg in kidney cancer

The U.S. Food and Drug Administration on Friday approved a label expansion for Merck’s (MRK) oral HIF-2α inhibitor belzutifan (Welireg) in combination with its...

Merck wins FDA label expansion for Welireg in kidney cancer
Simply Wall St 3d
Merck Expands Animal Health Automation And Traceability With TARGAN And Hedera

Merck Animal Health has agreed to acquire TARGAN, a poultry biodevice company focused on high speed gender identification and vaccine delivery. The company is...

Merck Expands Animal Health Automation And Traceability With TARGAN And Hedera
Nasdaq 3d
Investors Heavily Search Merck & Co., Inc.: Here is What You Need to Know

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influenc...

Investors Heavily Search Merck & Co., Inc.: Here is What You Need to Know
Nasdaq 3d
Merck Animal Health To Acquire TARGAN To Expand Poultry Technology Portfolio

(RTTNews) - Merck Animal Health, a division of Merck & Co. (MRK), on Thursday announced a definitive agreement to acquire TARGAN, a privately held developer of...

Merck Animal Health To Acquire TARGAN To Expand Poultry Technology Portfolio
Simply Wall St 4d
Assessing Merck Valuation After Recent Trading Dip And Oncology Pipeline Expectations

Advertisement Merck stock snapshot after recent trading move Merck (MRK) moved slightly lower in the latest trading session, with the stock closing at US$119....

Assessing Merck Valuation After Recent Trading Dip And Oncology Pipeline Expectations
Zacks 4d
Top Research Reports for Merck, Southern Company & Lumentum

Wednesday, June 10, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports...

Top Research Reports for Merck, Southern Company & Lumentum
Benzinga 5d
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

While the combo showed a numerical improvement in progression-free survival, it did not reach statistical significance, and investigators said the probability o...

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.